about
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroDexamethasone and betamethasone administration during pregnancy affects expression and function of 11 beta-hydroxysteroid dehydrogenase type 2 in the rat placentaZonation of multidrug resistance-associated protein 2 in rat liver after induction with dexamethasoneReciprocal changes in maternal and fetal metabolism of corticosterone in rat during gestationExamination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in ratOlomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.Breast cancer resistance protein (BCRP/ABCG2).Etravirine inhibits ABCG2 drug transporter and affects transplacental passage of tenofovir disoproxil fumarate.P-glycoprotein in the placenta: expression, localization, regulation and function.Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine.Variation of drug kinetics in pregnancy.Tetratricopeptide repeat motifs in the world of bacterial pathogens: role in virulence mechanisms.Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics.Regulation of drug transporter expression and function in the placenta.Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP.Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression.Salicylanilide acetates: synthesis and antibacterial evaluation.Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines.Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver.Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-butylbenzoxazoles.Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats.Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms.Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility.Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats.Influence of P-glycoprotein on the transplacental passage of cyclosporine.Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats.Corticosterone transfer and metabolism in the dually perfused rat placenta: effect of 11beta-hydroxysteroid dehydrogenase type 2.Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
P50
Q28534229-AE021065-35B3-49D8-8FAD-B72ABE735C7DQ28537944-C1607D8D-8BF3-4AA9-AEF3-4D35E6FA79CAQ28565422-1F4CB0BA-F857-42C6-ADD0-52A63FE66902Q28573886-24AA0924-F6F3-4342-A27D-977429569642Q28575896-99F43733-E993-4721-80C5-74208ECD7F84Q28577042-E5EEE168-32E7-4C3B-8547-8D9295950CCBQ28581689-2059AB23-47D2-43D3-BFFF-D3CECF6E302CQ34102279-D85A6B36-7EA8-496C-89FF-F8432DEE7A73Q34391489-49E3AB92-A3AA-43C1-ADE6-5C53E1A33174Q36174277-ABEF805B-83C8-4B80-B723-112A9729B69CQ36431006-97CE226E-819D-4414-A787-25FB03E2BE3FQ37203806-CAA2AD73-4AFC-44B8-A328-D2452790020DQ37581651-2123604B-6F7F-433C-AD47-D68D6791FBC3Q38069528-87C3BE90-D0E1-449C-A439-7076FE0E02D7Q38119818-1CC243AF-B44C-416C-BAB8-4DBD02865555Q38323562-72F80A47-263F-464F-A858-F2B269DD6913Q39035326-735BCFF2-EA83-4EBE-8D19-B8C831FC2738Q39938478-75D889B0-5613-47D8-9331-B4164EF041DFQ40052938-9851D1C1-2544-4351-8149-47D9650C681EQ40095099-27F9C429-99E3-46DE-BE1A-C9C90B818ECFQ40119245-A1797926-147A-429F-8CB7-49D65642FE99Q40148984-3271D567-A198-47E2-B766-7B0F147B6C08Q40152929-3D4EC0BF-CB29-4AF2-9AEC-1D528BE4DFFFQ40245874-2F4CAE33-96BC-4D73-89E7-82B2C0EB625CQ40265709-3382DDC2-FAE2-4DB4-A25B-475134AA2EF5Q40323422-11EC18AE-E5A1-48E7-8712-D0D8C8239F38Q40926668-4DBED0CA-2071-4FB4-85E8-BB6DF2AA5183Q41601248-2FA43F59-0BBB-4DCD-A9D1-83D39CC32C1DQ42491474-FCD36F85-3E4F-4DB3-8E46-26C7CDA611D3Q42702286-F56435A6-ACB1-4CA1-8C0E-49712C36CD38Q43271761-02026B05-4145-4EE4-A674-54E6CCD5C3A2Q43286907-59F738DE-6848-4DE2-9EFD-A464EE81AE7FQ43824716-C64E840D-C205-4B30-B264-95C0337D14C8Q46544384-FA7A8C32-B775-44F5-8975-D00E89288BB2Q46843323-7607BA0B-B5D7-4561-BB53-2640347C6E53Q46984881-B9755D86-1EE9-415F-B592-4851FF5C35C9Q47912038-95B10692-387E-4FA8-B83B-B37EF5F76EFBQ48145638-E9EF5820-F386-48DF-92D4-100FE3812E22Q53816970-0260CFD0-C32C-41CE-8DBE-032098DC1926Q53818047-F494B88A-79D3-4E84-8433-88441725CF06
P50
description
researcher
@en
name
Frantisek Staud
@en
Frantisek Staud
@nl
type
label
Frantisek Staud
@en
Frantisek Staud
@nl
prefLabel
Frantisek Staud
@en
Frantisek Staud
@nl
P106
P31
P496
0000-0001-6712-097X